Cancer Biological Therapy Market to Grow with a CAGR of 7.69% through 2030
Rising Immunotherapy Combinations and growing demand
of Chimeric
Antigen Receptor T-cell (CAR-T) therapy is expected to drive the Global Cancer Biological
Therapy Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Cancer
Biological Therapy Market – Global Industry Size, Share,
Trends, Competition, Forecast & Opportunities, 2020-2030F”, the Global
Cancer Biological Therapy Market stood at USD 112.08 Billion in 2024 and is
expected to reach USD 147.92 Billion by 2030 with a CAGR of 7.69% during the
forecast period.
Immunotherapy has emerged as a transformative force in
the treatment of various cancers, offering an alternative to traditional
therapies such as chemotherapy and radiation. The next frontier in this field
is the combination of multiple immunotherapies or integrating immunotherapy
with other therapeutic approaches. The synergy between various immune-based
therapies—such as checkpoint inhibitors, chimeric antigen receptor T-cell
(CAR-T) therapy, and cancer vaccines—holds the potential to significantly enhance
therapeutic outcomes. Checkpoint inhibitors, like PD-1/PD-L1 inhibitors, work
by blocking the mechanisms that cancer cells use to evade the immune system,
while CAR-T cell therapy involves modifying a patient's own T cells to target
and destroy cancer cells. Meanwhile, cancer vaccines stimulate the immune
system to recognize and fight cancer more effectively. The combination of these
therapies is particularly promising because it can potentially overcome the
limitations of each approach when used alone, such as immune resistance or
insufficient tumor targeting. Researchers are investigating how these therapies
can be combined at different stages of cancer treatment to achieve better
long-term outcomes, potentially leading to cures in some cancers that are
currently difficult to treat. The rising interest in immunotherapy combinations
is also spurred by the increasing number of clinical trials and promising
early-stage data, making this an exciting area for both researchers and
clinicians. As this trend develops, we expect immunotherapy combinations to
become more standard in the treatment of various cancer types, enhancing
patient outcomes and broadening the scope of immunotherapy's effectiveness.
The concept of precision medicine in oncology, guided
by the identification and use of specific biomarkers, is rapidly gaining
prominence. Biomarker-driven therapies are pivotal for offering more
personalized treatment options, ensuring that each patient receives the most
effective and tailored treatment based on their tumor’s unique molecular
characteristics. Tumor biomarkers, such as specific genetic mutations, gene
expressions, and molecular signatures, provide critical insights into the
biology of cancer and can help predict how patients will respond to certain
therapies. With advancements in genomic technologies, a growing number of
biomarkers are being identified, allowing for the development of highly
targeted therapies that minimize side effects by focusing on cancer cells
without affecting healthy tissue. This approach is particularly effective in
cancers where traditional treatments have been less effective. For example,
targeted therapies that inhibit specific mutations or disrupt molecular pathways
involved in tumor growth are now being used in clinical practice for cancers
such as non-small cell lung cancer, melanoma, and breast cancer. In addition to
guiding treatment choices, biomarkers also play a crucial role in monitoring
patient progress, detecting relapses, and determining the most appropriate
timing for interventions. The continued discovery of new biomarkers will likely
drive further advancements in biomarker-driven therapies, leading to more
effective treatments, improved survival rates, and the ability to treat cancers
that were previously considered untreatable. As these approaches evolve, the
integration of biomarkers in routine clinical practice will be pivotal in
transforming cancer care into a more precise, patient-centered approach.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Cancer Biological Therapy Market”
The Global Cancer Biological Therapy Market is
segmented into product, distribution channel, regional distribution, and
company.
Based on product, The Monoclonal Antibodies sector is expected to be the fastest-growing segment in 2024. These antibodies are gaining significant traction, especially in cancer therapy, due to their ability to precisely target proteins on the surface of cells. This high level of precision is making them increasingly valuable, particularly as patients and healthcare providers shift towards advanced biological therapies to reduce the risks associated with traditional anti-cancer treatments. Monoclonal antibodies, such as rituximab for non-Hodgkin’s lymphoma, alemtuzumab for chronic leukemia, and ipilimumab for melanoma, are transforming cancer treatment by targeting protein molecules expressed by malignant tumors. Furthermore, trastuzumab, used in breast cancer treatment, is an example of how these antibodies inhibit cancer cell growth by binding specifically to targeted areas on the cells. This growing preference for biologics is expected to drive rapid expansion in the monoclonal antibodies sector, making it a leader in the market..
Based on region, The second most dominating region in
the cancer biological therapy market was Europe. Europe has
a well-established healthcare infrastructure, which supports the widespread
adoption of innovative cancer therapies, including biological treatments. The
region’s strong regulatory framework and presence of leading pharmaceutical
companies further contribute to its prominence in the market. Key European
countries, such as Germany, France, the United Kingdom, and Italy, are
significant contributors to the cancer biological therapy market. These
countries invest heavily in research and development (R&D), driving the
discovery and approval of new cancer therapies. Europe has a high
cancer burden, which fuels the demand for effective treatments, including
monoclonal antibodies, cancer vaccines, and cancer growth blockers.
The European Medicines Agency (EMA) plays a pivotal
role in the regulatory approval process, ensuring that new therapies meet
rigorous safety and efficacy standards. This, coupled with robust reimbursement
systems in many European countries, helps facilitate the widespread adoption of
innovative cancer therapies. The market in Europe is also supported by
increasing healthcare expenditures, a growing aging population, and rising
awareness about cancer treatment options. the region is home to
numerous clinical trials, fostering innovation and providing patients with
access to cutting-edge therapies. The growth of personalized medicine and
immunotherapies, including combination therapies, is particularly notable in
Europe, contributing to the overall expansion of the market. As a result,
Europe continues to be a major player in the global cancer biological therapy
market, following North America in terms of market share.
Major companies operating in Global Cancer
Biological Therapy Market are:
- F
Hoffmann-La Roche Ltd
- Novartis
AG
- Merck
KgAa
- Amgen
Inc
- GSK
PLC
- Celgene
Corporation
- Pfizer
Inc
- Zydus
Lifesciences Ltd
- Sun
Pharmaceutical Industries Ltd
- Bayer
AG
Download Free Sample Report
Customers can also request for 10% free customization
on this report
“Chimeric Antigen Receptor T-cell (CAR-T) therapy has
shown remarkable success in treating certain blood cancers, such as leukemia
and lymphoma. This immunotherapy technique involves extracting a patient’s T
cells, genetically modifying them to recognize cancer-specific antigens, and
then reintroducing them into the patient’s body to target and eliminate cancer
cells. The success of CAR-T therapies, particularly in patients who have
exhausted other treatment options, has garnered significant attention. As research
continues to evolve, CAR-T cell therapy is expected to expand beyond
hematologic cancers and enter the realm of solid tumors, which have
historically been more difficult to treat with immunotherapies. Studies are
underway to identify the right tumor antigens, optimize CAR-T cell delivery to
solid tumors, and overcome challenges such as the immunosuppressive tumor
microenvironment. If successful, this expansion could revolutionize treatment
options for solid tumors like breast cancer, lung cancer, and colorectal
cancer, providing new hope for patients who have limited treatment
alternatives. The development of next-generation CAR-T therapies
aims to improve the efficacy and safety of the treatment by enhancing the
persistence and activity of CAR-T cells, reducing side effects, and enabling
the treatment to be more widely available. This could involve engineering CAR-T
cells with better targeting capabilities or developing off-the-shelf CAR-T
therapies that eliminate the need for personalized cell collection.,” said Mr.
Karan Chechi, Research Director of TechSci Research, a research-based management
consulting firm.
“Cancer
Biological Therapy Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, Segmented By Product (Cancer Growth Blockers, Monoclonal
Antibodies, Vaccines), By Distribution Channel (Hospitals, Retail & Mail
Order Pharmacies), By Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global
Cancer Biological Therapy Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Cancer
Biological Therapy Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com